Christensenella minuta as Next Generation Probiotics
Background C. minuta and health Products FAQs Resources
Christensenella minuta is a recently described gastrointestinal bacterium that plays a significant role in the prevention of obesity. Here, Creative Biolabs provides a comprehensive range of high-quality services and support for the development of probiotics based on Christensenella minuta.
Brief Introduction to Christensenella minuta
Christensenella minuta (C. minuta) is a recently identified as a gram-negative bacterium belonging to the genus of Christensenella and the family of Christensenellaceae. C. minuta was first discovered in 2012 from the feces of a healthy donor. As a Gram-negative bacterium, C. minuta mainly distributes in the human gastrointestinal tract, which is a strictly anaerobic environment.
Structurally, C. minuta is a kind of non-spore-forming and non-motile bacterium with short-rod shape (approximately 0.4×0.8-1.9 µm) and a tapered end, which sometimes presents in pairs with a rounded coccobacillary shape. When cultured in Gifu anaerobic medium, circular and beige C. minuta colonies are formed with a 0.1-0.2 mm in diameter. The most optimal growth conditions of C. minuta are 37-40 ℃ in temperature and at pH 7.5.
Fig.1 Morphology of Christensenella minuta strain YIT 12065. (Morotomi, 2012)
Christensenella minuta and Human Health
As a critical microbiome in the human gut, C. minuta has been indicated to be closely associated with human health improvement in an unknown biological mechanism. Numerous fecal samples research demonstrated that the presence or absence and amount of C. minuta could affect the obesity and related metabolic disorders risk of an individual. C. minuta tended to be more abundant in individuals with low body mass index (BMI) or lean body. Also, it has been found that C. minuta was highly heritable, and had an impact on obesity-associated microbiomes and other heritable probiotic bacteria in human and mice gut.
All this evidence suggests the great potential and possible therapeutic uses of C. minuta as probiotics in terms of obesity and related gastrointestinal disorders. A full understanding of C. minuta genome and its possible biological mechanisms will help us better understand not only the relationship between C. minuta and obesity and gastrointestinal diseases but also the relationship between host genetics and intestinal microbiome, meanwhile, it may also open the door to the development of probiotics therapies and live biotherapeutics.
The development of intestinal microflora and its effects on gastrointestinal health have been the focus of research in recent years. As a biotechnology company keeping pace with times, Creative Biolabs has invested numerous energy and efforts in the development of probiotics-based drug discovery. We now provide a full range of optimized probiotic services for the treatment of related diseases.
Please feel free to contact us and our experienced technicians will give you the most detailed answers to your questions.
Related Products
|
CAT
|
Product Name
|
Product Overview
|
|
LBST-046FG
|
Christensenella minuta
|
Christensenella minuta is an anaerobe, mesophilic, Gram-negative bacterium that was isolated from faeces from a healthy Japanese male.
|
|
LBST-047FG
|
Christensenella massiliensis
|
Christensenella is a Gram-negative, strictly anaerobic genus of bacteria first discovered in the human gut. Christensenella massiliensis was isolated from human stool specimen from a 66-year-old patient.
|
|
LBST-048FG
|
Christensenella timonensis
|
Christensenella is a Gram-negative, strictly anaerobic genus of bacteria first discovered in the human gut. Christensenella timonensis was isolated from human stool specimen from a 66-year-old patient.
|
FAQs
How can C. minuta probiotic discovery service benefit researchers?
The C. minuta probiotic discovery service provides researchers with a comprehensive platform for exploring the therapeutic potentials of this bacterium. This service includes strain isolation, genetic sequencing, and functional analysis, offering valuable insights into its mechanism of action and potential health benefits. This enables scientists to further understand its role within the gut microbiome and its implications for human health.
Are there any specific applications of C. minuta in research?
C. minuta has diverse applications in research, particularly in studies focused on obesity, metabolic health, and gut microbiota composition. Its potential for modulating the gut microbiome makes it a valuable subject for investigating the complex interactions between diet, microbiota, and host metabolic health.
What are the limitations of using C. minuta products and services?
While C. minuta offers promising prospects, its products and services are currently limited to research purposes only and are not approved for diagnostic or therapeutic use in humans. This limitation is due to the need for extensive clinical trials to fully understand its safety, efficacy, and potential side effects when used as a treatment.
Resources
Reference
-
Morotomi, M.; et al. Description of Christensenella minuta gen. nov., sp. nov., isolated from human feces, which forms a distinct branch in the order Clostridiales, and proposal of Christensenellaceae fam. nov. International Journal of Systematic and Evolutionary Microbiology. 2012, 62: 144-149.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
